RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Editas Medicine Stock

Editas Medicine ROCE 2025

Editas Medicine ROCE

-1.78

Ticker

EDIT

ISIN

US28106W1036

WKN

A2AC4K

In 2025, Editas Medicine's return on capital employed (ROCE) was -1.78, a 267.16% increase from the -0.48 ROCE in the previous year.

Editas Medicine Aktienanalyse

What does Editas Medicine do?

Editas Medicine Inc. is a rising biopharmaceutical company specializing in the development of groundbreaking therapies based on genome editing. Its goal is to combat genetic diseases and other genetically related disorders by selectively modifying DNA sequences. The company was founded in 2013 by a group of renowned scientists, including prominent genome editors Jennifer Doudna and George Church. Over the years, Editas Medicine Inc. has established itself as a pioneer in the field of genome editing and has received numerous awards and funding. Its business model revolves around researching and developing innovative therapies based on genetic modifications, using approaches such as CRISPR/Cas9, TALEN, and zinc finger nucleases. The company aims to develop treatments for previously incurable, severe diseases. Its activities are divided into various business areas, including the exploration of gene therapies, the development of medications based on CRISPR/Cas9 technology, and the research of genome-based diagnostic options. Editas Medicine Inc. has already introduced some products to the market or is in advanced stages of development, such as the medication LCA10 for a rare form of blindness and the medication CEP290 for a severe genetic disease. Overall, Editas Medicine Inc. has experienced remarkable growth in recent years, becoming one of the key players in genome editing. The market for gene therapies and genome-based treatments has significant growth potential, making the company's prospects promising. Editas Medicine Inc. is dedicated to advancing genomic medicine by developing groundbreaking solutions for incurable diseases and providing a platform for new technologies in the market. Editas Medicine ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Editas Medicine's Return on Capital Employed (ROCE)

Editas Medicine's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Editas Medicine's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Editas Medicine's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Editas Medicine’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Editas Medicine stock

What is the ROCE (Return on Capital Employed) of Editas Medicine this year?

The ROCE of Editas Medicine is -1.78 undefined this year.

How has the ROCE (Return on Capital Employed) of Editas Medicine developed compared to the previous year?

The ROCE of Editas Medicine has increased by 267.16% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Editas Medicine?

A high Return on Capital Employed (ROCE) indicates that Editas Medicine has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Editas Medicine?

A low ROCE (Return on Capital Employed) can indicate that Editas Medicine has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Editas Medicine impact the company?

An increase in the ROCE of Editas Medicine can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Editas Medicine affect the company?

A decrease in ROCE of Editas Medicine can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Editas Medicine?

Some factors that can affect Editas Medicine's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Editas Medicine so important for investors?

The ROCE of Editas Medicine is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Editas Medicine take to improve the ROCE?

To improve the ROCE, Editas Medicine can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Editas Medicine pay?

Over the past 12 months, Editas Medicine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Editas Medicine is expected to pay a dividend of 0 USD.

What is the dividend yield of Editas Medicine?

The current dividend yield of Editas Medicine is .

When does Editas Medicine pay dividends?

Editas Medicine pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Editas Medicine?

Editas Medicine paid dividends every year for the past 0 years.

What is the dividend of Editas Medicine?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Editas Medicine located?

Editas Medicine is assigned to the 'Health' sector.

Wann musste ich die Aktien von Editas Medicine kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Editas Medicine from 10/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2025.

When did Editas Medicine pay the last dividend?

The last dividend was paid out on 10/4/2025.

What was the dividend of Editas Medicine in the year 2024?

In the year 2024, Editas Medicine distributed 0 USD as dividends.

In which currency does Editas Medicine pay out the dividend?

The dividends of Editas Medicine are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Editas Medicine stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Editas Medicine

Our stock analysis for Editas Medicine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Editas Medicine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.